We studied the effects of recombinant granulocytic CSF on heart remodeling in BALB/c mice after cryodestruction. Administration of granulocytic CSF was started 1 day after cryodestruction (subcutaneously, 10 μg/kg/day, for 4 days). As early as after the first injection, leukocytosis in the peripheral blood started to develop, leukocyte count peaked on days 4-6 and returned to normal on day 14. Treatment with granulocytic CSF significantly increased the content of progenitor cells in the bone marrow and led to rapid development of the inflammatory reaction and myocardium infiltration with mononuclear cells. Injections of granulocytic CSF did not reduce scar area, but provided significantly less pronounced heart hypertrophy, which attests to its better functional properties. By day 30 after cryodestruction, control animals and animals receiving granulocytic CSF exhibited similar morphological picture at the site of damage. Thus, our regimen of granulocytic CSF administration produced a mobilizing effect on bone marrow progenitor cells and postinfarction heart remodeling. Direct effects of granulocytic CSF on the heart have to be established for its use in the treatment of myocardial infarction.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Yu. I. Buziashvili, S. T. Matskeplishvili, B. G. Alekyan, et al., Vestn. Ros. Akad. Med. Nauk, No. 4, 65-69 (2005).
A. E. Vermel’, Klin. Med., No. 1, 5-11 (2004).
N. A. Onishenko, I. V. Potapov, L. V. Bashkina, et al., Bull. Eksp. Biol. Med., 138, No. 10, 403-407 (2004).
L. A. Stavrova, G. I. Folina, M. B. Plotnikov, et al., Kletochn. Tekhn. Biol. Med., No. 4, 190-194 (2005).
Y. Dai, M. Ashraf, S. Zuo, et al., J. Mol. Cell. Cardiol., 44, No. 3, 607-617 (2008).
J. Honold, R. Lehmann, C. Heeschen, et al., Arterioscler. Thromb. Vasc. Biol., 26, No. 10, 2238-2243 (2006).
P. Kanellakis, N. J. Slater, X. J. Du, et al., Cardiovasc. Res., 70, No. 1, 117-125 (2006).
Y. Li, N. Fukuda, S. Yokoyama, et al., Eur. J. Pharmacol., 549, Nos. 1-3, 98-106 (2006).
T. Sakai, R. K. Li, R. D. Weisel, et al., Ann. Thorac. Surg., 68, No. 6, 2074-2080 (1999).
C. Sesti, S. L. Hale, C. Lutzko, and R. A. Kloner, J. Am. Coll. Cardiol., 46, No. 9, 1662-1669 (2005).
H. Takano, K. Ueda, H. Hasegawa, and I. Komuro, Trends Pharmacol. Sci., 28, No. 10, 512-517 (2007).
S. Vandervelde, M. J. van Luyn, R. A. Tio, and M. C. Harmsen, J. Moll. Cell. Cardiol., 39, No. 2, 363-376 (2005).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Kletochnye Tehnologii v Biologii i Medicine, No. 1, pp. 23-25, January, 2010
Rights and permissions
About this article
Cite this article
Afanas’ev, S.A., Rogovskaya, Y.V., Ryabov, V.V. et al. Evaluation of the Efficacy of Granulocytic Colony-Stimulating Factor for the Treatment of Experimental Myocardial Destruction in Mice. Bull Exp Biol Med 149, 131–134 (2010). https://doi.org/10.1007/s10517-010-0891-6
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-010-0891-6